Therapeutic options in mantle cell lymphoma

References

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's Lymphoma. Blood 1997; 89: 3909–3918
   PubMed Web of Science ®Google Scholar
• E S Jaffe, Harris, N L, Stein, H, Vardiman, J W. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press. 2001
   Google Scholar
• Campo E, Raffeld M, Jaffe E S. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127
   PubMed Web of Science ®Google Scholar
• Bosch F, Lopez-Guillermo A, Campo E, Ribera J M, Conde E, Piris M A, et al. Mantle cell lymphoma presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567–575
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, Dreyling M H, Campo E, Norton A, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131: 29–38
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Medeiros L J, Hagemeister F B, Fayad L E, Rodriguez M A, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97: 586–591
   PubMed Web of Science ®Google Scholar
• Liu Z, Dong H Y, Gorczycz W, Tsang P, Cohen P, Stephenson C F, et al. CD5− mantle cell lymphoma. Am J Clin Pathol 2002; 118: 216–224
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, Chan W C, Connors J M, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger D D, Greiner T C, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315–4321
   PubMed Web of Science ®Google Scholar
• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Andersen N S, Jensen M K, de Nully Brown P, Geisler C H. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002; 38: 401–408
   PubMed Web of Science ®Google Scholar
• Sweetenham J W. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?. Bone Marrow Transplant 2001; 28: 813–820
   PubMed Web of Science ®Google Scholar
• Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975–4981
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257–262
   PubMed Web of Science ®Google Scholar
• Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, et al. Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history. Haematologica 1998; 83: 312–316
   PubMed Web of Science ®Google Scholar
• Weisenburger D D, Vose J M, Greiner T C, Lynch J C, Chan W C, Bierman P J, et al. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64: 190–196
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event free-survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587–593
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Khouri I F, Kantarjian H M, Hagemeister F B, Rodriguez M A, McLaughlin P, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma 2000; 39: 77–85
   PubMed Web of Science ®Google Scholar
• Cohen B J, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42: 1015–1022
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomised study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S, Bertoni F, Waltzer U, Fey M F, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705–711
   PubMed Web of Science ®Google Scholar
• Foran J M, Rohatiner A Z, Cunningham S, Popescu R A, Solal-Celigny P, Ghielmini M, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317–324
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Bock H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• Kahl B S, Longo W L, Eickhoff J C, Zehnder J, Jones C, Blank J. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17: 1418–1423
   PubMed Web of Science ®Google Scholar
• Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006; 12: 1270–1276
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992
   PubMed Web of Science ®Google Scholar
• Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 2004; 104: 584
   Web of Science ®Google Scholar
• Schultz H, Bohlius J F, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706–714
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Inwards D J, Hillman D W, Fishkin P A, White W L, Morton R F, Dakhil S R, et al. Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL). J Clin Oncol 2006; 24: 17505
   Google Scholar
• Thomas D W, Owen R G, Johnson S A, Hillmen P, Seymour J F, Wolf M M, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005; 46: 549–552
   PubMed Web of Science ®Google Scholar
• Bauwens D, Maerevoet M, Michaux L, Theate I, Hagemijer A, Stul M, et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005; 131: 338–340
   PubMed Web of Science ®Google Scholar
• Zelenetz A D, Noy A, Pandit-Taskar N, Scordo M, Rijo I, Zhou Y, et al. Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol 2006; 24: 7560
   Google Scholar
• Jurczak W, Giza A, Szostek M, Hubalewska-Dydejzyk A, Sowa-Staszczak A, Knopinska-Poluszny W, et al. 90Y-Zevalin® (90Y-Ibritumomab Tiuxetan) radioimmunotherapy (RIT) consolidation of FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: results from the PLRG upon completed enrollment. Blood 2006; 108: 2747
   Google Scholar
• Smith M R, Chen H, Gordon L, Foran J, Kahl B, Advani R, et al. Phase II study of rituximab + CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499). J Clin Oncol 2006; 24: 7503
   Google Scholar
• Weigert O, Jurzcak C, Von Schilling C, Giza A, Rummel M, Hubalewska A, et al. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG. J Clin Oncol 2006; 24: 7533
   Google Scholar
• Younes A, Pro B, Rodriguez M A, Romaguera J E, McLaughlin P, Wang M, et al. Activity of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL). Blood 2005; 106: 2452
   PubMed Web of Science ®Google Scholar
• Freedman A S, Neuberg D, Gribben J G, Mauch P, Soiffer R J, Fisher D C, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16: 13–18
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684
   PubMed Web of Science ®Google Scholar
• Khouri I F, Saliba R M, Okoroji G J, Acholonu S A, Champlin R E. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of β-2-microglobulin and the tumor score. Cancer 2003; 98: 2630–2635
   PubMed Web of Science ®Google Scholar
• Andersen N S, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K, et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003; 71: 73–80
   PubMed Web of Science ®Google Scholar
• Geisler C H, Elonen E, Kolstad A, Laurell A, Andersen N S, Pedersen L B, et al. Nordic mantle cell lymphoma (MCL) project: prolonged follow-up of 86 patients treated with BEAM/BEAC + PBSCT confirms that addition of high-dose Ara-C and rituximab to CHOP induction + in-vivo purging with rituximab increases clinical and molecular response rates, PCR-Neg. grafts, failure-free, relapse-free and overall survival. Blood 2004; 104: 8
   Web of Science ®Google Scholar
• Mangel J, Leitch H A, Connors J M, Buckstein R, Imrie K, Spaner D, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15: 283–290
   PubMed Web of Science ®Google Scholar
• Dreger P, Rieger M, Seyfarth B, Hensel M, Kneba M, Ho A D. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007; 92: 42–49
   PubMed Web of Science ®Google Scholar
• Gianni A M, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749–755
   PubMed Web of Science ®Google Scholar
• Vandenberghe E, Ruiz de Elvira C, Loberiza Fr, Conde E, Lopez-Guillermo A, et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet A S, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104: 1434–1441
   PubMed Web of Science ®Google Scholar
• Vose J, Loberiza F, Bierman P, Bociek G, Armitage J. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/high-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol 2006; 24: 7511
   Google Scholar
• Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107: 2271–2278
   PubMed Web of Science ®Google Scholar
• Ritchie D S, Seymour J F, Grigg A P, Roberts A W, Hoyt R, Thompson S, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007; 86: 101–105
   PubMed Web of Science ®Google Scholar
• Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kroger N, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1: 87–94
   PubMedGoogle Scholar
• Kasamon Y L, Jones R J, Diehl L F, Nayer H, Borowitz M J, Garrett-Mayer E, et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005; 11: 39–46
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Levy V, Delarue R, Baret B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004; 89: 1275–1276
   PubMed Web of Science ®Google Scholar
• Howard O M, Gribben J G, Neuberg Ds, Grossbard M, Poor C, Janicek M J, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–1294
   PubMed Web of Science ®Google Scholar
• Gopal A K, Ranjendran J G, Petersdorf S H, Maloney D G, Eary J F, Wood B L, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158–3162
   PubMed Web of Science ®Google Scholar
• Gopal A K, Rajendran J G, Cooley T A, Pagel J M, Fisher D R, Petersdorf S H, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25: 1396–1402
   PubMed Web of Science ®Google Scholar
• Khouri I F, Lee M S, Saliba R M, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407–4412
   PubMed Web of Science ®Google Scholar
• Maris M B, Sandmaier B M, Storer B E, Chauncey T, Stuart M J, Maziarz Rt, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004; 104: 3532–3542
   Web of Science ®Google Scholar
• Khouri I F, Lee M S, Romaguera J, Mirza N, Kantarjian H, Korblin M, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293
   PubMed Web of Science ®Google Scholar
• Popplewell L L, Nademanee A, Carter N, Zain J, Krishnan A, Rodriguez R, et al. Autologous vs. allogeneic cell transplantation for mantle cell lymphoma (MCL): outcomes over a 10-year period at city of hope. Blood 2004; 104: 894
   Google Scholar
• Ganti A K, Bierman P J, Lynch J C, Bociek R G, Vose J M, Armitage J O. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005; 16: 618–624
   PubMed Web of Science ®Google Scholar
• Robinson S P, Goldstone A H, Mackinnon S, Carella A, Russell N, De Elvira C R, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316
   PubMed Web of Science ®Google Scholar
• Avivi I, Canals C, Taghipour G, Finke J, Volin L, Beguin Y, et al. Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma. A retrospective analysis from the EBMT Lymphoma Working Party. Blood 2006; 108: 3123
   Google Scholar
• Belch A, Kouroukis C T, Crump M, Sehn L, Gascoyne R D, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116–121
   PubMed Web of Science ®Google Scholar
• Leonard J P, Furman R R, Cheung Y-KK, Feldman E J, Cho H J, Vose J M, et al. Phase I/II trial of Bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results. Blood 2005; 106: 491
   Google Scholar
• Kouroukis C T, Belch A, Crump M, Eisenhauer E, Gascoyne R D, Meyer R, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 1740–1745
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257–264
   PubMed Web of Science ®Google Scholar
• Fisher R I, Bernstein S H, Kahl B S, Djulbegovic B, Robertson M J, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• O'Connor O A, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684
   PubMed Web of Science ®Google Scholar
• Witzig T E, Geyer S M, Ghobrial I, Inwards D J, Fonseca R, Kurtin P, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347–5356
   PubMed Web of Science ®Google Scholar
• Ruan J, Coleman M, Furman R R, Glynn P, Joyce M, Ketas J, et al. Targeting angiogenesis in mantle cell lymphoma: clinical efficacy and correlative studies of a phase II trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in relapsed/refractory disease. Blood 2006; 108: 2751
   Google Scholar
• Kaufmann H, Raderer M, Wohrer S, Puspok A, Bankier A, Zielinski C, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 2269–2271
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Hagemeister F, Neelapu S, Bell N, Byrne C, et al. A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 2007; 25: 8030
   Google Scholar